Analyst Rating Update: Barclays analyst Adrienne Yih has reduced the price target for Bath & Body Works from $32 to $31 while maintaining an Equal Weight rating on the shares.
Performance Insights: The company's Q2 results showed lower sales than expected but exceeded earnings and gross margin estimates; however, guidance for fiscal year earnings was downgraded due to weak traffic and issues with the semiannual sale execution.
BBWI
$20.22+Infinity%1D
Analyst Views on BBWI
Wall Street analysts forecast BBWI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBWI is 30.50 USD with a low forecast of 15.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast BBWI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBWI is 30.50 USD with a low forecast of 15.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
6 Hold
0 Sell
Moderate Buy
Current: 19.640
Low
15.00
Averages
30.50
High
43.00
Current: 19.640
Low
15.00
Averages
30.50
High
43.00
Guggenheim
Simeon Siegel
Neutral
initiated
2025-12-09
Reason
Guggenheim
Simeon Siegel
Price Target
2025-12-09
initiated
Neutral
Reason
Guggenheim analyst Simeon Siegel initiated coverage of Bath & Body Works with a Neutral rating and no price target. The retail sector still seems to be perceived as "structurally sick," but the firm says "holiday brought the cheer," tariffs have been manageable so far and "most importantly and likely going unnoticed" is the fact that the majority of the firm's coverage actually operates at, or close to, their gross margin peaks.
UBS
Neutral
downgrade
$32 -> $17
2025-11-21
Reason
UBS
Price Target
$32 -> $17
2025-11-21
downgrade
Neutral
Reason
UBS lowered the firm's price target on Bath & Body Works to $17 from $32 and keeps a Neutral rating on the shares. Bath & Body Works' Q3 report is likely a negative catalyst for the stock, the analyst tells investors in a research note.
Telsey Advisory
Telsey
Market Perform
downgrade
$38 -> $17
2025-11-21
Reason
Telsey Advisory
Telsey
Price Target
$38 -> $17
2025-11-21
downgrade
Market Perform
Reason
Telsey Advisory lowered the firm's price target on Bath & Body Works to $17 from $38 and keeps a Market Perform rating on the shares. Bath & Body's Q3 results missed expectations due to softer sales and weaker margins, with Q4 guidance signaling continued challenges amid macro pressure, the analyst tells investors in a research note. While the company remains a well-known brand with a loyal customer base, recovery is taking longer than anticipated, and topline and margin improvement is unlikely until the second half of 2026, limiting near-term visibility, Telsey says.
Telsey Advisory
Dana Telsey
Outperform -> Market Perform
downgrade
$38 -> $17
2025-11-21
Reason
Telsey Advisory
Dana Telsey
Price Target
$38 -> $17
2025-11-21
downgrade
Outperform -> Market Perform
Reason
Telsey Advisory analyst Dana Telsey downgraded Bath & Body Works to Market Perform from Outperform with a price target of $17, down from $38. Bath & Body's Q3 results missed expectations due to softer sales and weaker margins, with Q4 guidance signaling continued challenges amid macro pressure, the analyst tells investors in a research note. While the company remains a well-known brand with a loyal customer base, recovery is taking longer than anticipated, and topline and margin improvement is unlikely until the second half of 2026, limiting near-term visibility, Telsey says.
About BBWI
Bath & Body Works, Inc. is a global omnichannel retailer focused on personal care and home fragrance. The Company offers a range of fragrances for the body and home, including selling collections for 3-wick candles, home fragrance diffusers, fine fragrance mists, liquid hand soaps, body lotions and body creams. It delivers customers their fragrances in multiple forms and categories. The Company sells merchandise through its retail stores in the United States and Canada, and through its Websites and other channels, under the Bath & Body Works, White Barn and other brand names. The Company’s international business is conducted through franchise, license and wholesale partners. It provides in-store experiences at more than 1,890 Company-operated Bath & Body Works locations in the United States and Canada, more than 525 international franchised locations and an online storefront at bathandbodyworks.com. Additionally, it offers a buy online pick-up in-store (BOPIS) option.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
